Research for applied and regulatory toxicology

  • Thresholds also for genotoxic carcinogens.
    Research at the (for example: Hengstler JG, Bogdanffy MS, Bolt HM and Oesch F, Challenging Dogma: Thresholds for Genotoxic Carcinogens, Annu Rev Pharmacol Toxicol, 43, 485-520, 2003, IF: 20,5) led to a strategy how under certain conditions threshold may also be justified for genotoxic carcinogens (“New European Legislation; Concept of the Scientific Committee on Occupational Exposure Limits (SCOEL, 2008): Carcinogens with thresholds”).
  • In vitro systems with hepatocytes have been recommended by the FDA as a standard technique. Research work at the (review: Hewitt et al., 2007) has contributed to the acceptance of primary hepatocyte in vitro systems as a standard for studies of drug metabolism, hepatotoxicity and enzyme induction (Guidance for Industry der U.S. Food and Drug Administration (FDA), 2006).

Selected publications

Hengstler JG, Bogdanffy MS, Bolt HM and Oesch F, Challenging Dogma: Thresholds for Genotoxic Carcinogens? The case of Vinyl Acetate, Annu Rev Pharmacol Toxicol, 43, 485-520, 2003.

Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007;39:159-234.

Hengstler JG, Utesch D, Steinberg P, Ringel M, Swales N, Biefang K, Platt KL, Diener B, Böttger T, Fischer T, Oesch F, Cryopreserved primary hepatocytes as an in vitro model for the evaluation of drug metabolism and enzyme induction. Drug Metab Rev 32, 81-118, 2000.

Streffer C, Bolt H, Follesdahl D, Hall P, Hengstler JG, Jakob P, Oughton D, Prieß K, Rehbinder E, Swaton E, Low dose exposures in the environment. Springer-Verlag, editor: C. Streffer, 470 pages, ISBN 3-540-21083-0, Heidelberg, 2004.

Bolt HM, Foth H, Hengstler JG, Degen G, Carcinogenicity categorization of chemicals – new aspects to be considered in a European perspective. Toxicology Letters 151, 29-41, 2004.

Dietrich D, Hengstler JG. From bisphenol A to bisphenol F and a ban of mustard due to chronic low-dose exposures? Arch Toxicol. 2016 Feb;90(2):489-91.

Gebel T, Foth H, Damm G, Freyberger A, Kramer PJ, Lilienblum W, Röhl C, Schupp T, Weiss C, Wollin KM, Hengstler JG. Manufactured nanomaterials: categorization and approaches to hazard assessment. Arch Toxicol. 2014 Dec;88(12):2191-211.

Gundert-Remy U, Damm G, Foth H, Freyberger A, Gebel T, Golka K, Röhl C, Schupp T, Wollin KM, Hengstler JG. High exposure to inorganic arsenic by food: the need for risk reduction. Arch Toxicol. 2015 Dec;89(12):2219-27.

Hengstler JG, Foth H, Gebel T, Kramer PJ, Lilienblum W, Schweinfurth H, Völkel W, Wollin KM, Gundert-Remy U. Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A. Crit Rev Toxicol. 2011 Apr;41(4):263-91.

Krug AK, Kolde R, Gaspar JA, Rempel E, Balmer NV, Meganathan K, Vojnits K, Baquié M, Waldmann T, Ensenat-Waser R, Jagtap S, Evans RM, Julien S, Peterson H, Zagoura D, Kadereit S, Gerhard D, Sotiriadou I, Heke M, Natarajan K, Henry M, Winkler J, Marchan R, Stoppini L, Bosgra S, Westerhout J, Verwei M, Vilo J, Kortenkamp A, Hescheler J, Hothorn L, Bremer S, van Thriel C, Krause KH, Hengstler JG, Rahnenführer J, Leist M, Sachinidis A. Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.

Waldmann T, Grinberg M, König A, Rempel E, Schildknecht S, Henry M, Holzer AK, Dreser N, Shinde V, Sachinidis A, Rahnenführer J, Hengstler JG, Leist M. Stem Cell Transcriptome Responses and Corresponding Biomarkers That Indicate the Transition from Adaptive Responses to Cytotoxicity. Chem Res Toxicol. 2016 Dec 21.